Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

Exclusion Criteria

• •Non-Selection Criteria:
• •Participants who meet at least one of the following criteria at the Screening Visit (Visit 1) will not be included into the study.
• •1. Any known allergy or hypersensitivity to GS010 or its constituents.
• •2. Contraindication to IVT injection.
• •3. IVT drug delivery to either eye within 30 days prior to the Screening Visit (Visit 1).
• •4. Previous vitrectomy in either eye.
• •5. Narrow angle in either eye contra-indicating pupillary dilation.
• •6. Presence of disorders of the ocular media, such as the cornea and lens, which may interfere with visual acuity and other ocular assessments during the study period.
• •7. Vision disorders, other than LHON, involving visual disability or with the potential to cause further vision loss during the trial period.
• •8. Causes of optic neuropathy other than LHON and glaucoma.
• •9. Participants with known mutations of other genes involved in pathological retinal or optic nerve conditions.
• •10. Presence of ocular or systemic disease, other than LHON, whose pathology or associated treatments might affect the retina or the optic nerve.
• •11. History of amblyopia associated with a Snellen visual acuity equivalent of worse than 20/80 (equivalent to 6/24 at 6 meters, decimal acuity 0.25, LogMAR +0.6) in the affected eye.
• •12. Presence of ocular conditions, which in the opinion of the Investigator will prevent good quality SD-OCT imaging from being obtained.
• •13. Presence, in either eye, of uncontrolled glaucoma, defined as an IOP greater than 25 mmHg, despite maximal medical therapy with intraocular pressure (IOP)-lowering agents.
• •14. Active ocular inflammation or history of idiopathic or autoimmune-associated uveitis.
• •15. Participants participating in another clinical trial and receiving an IMP within 90 days prior to the Screening Visit (Visit 1).
• •16. Previous treatment with an ocular gene therapy product.
• •17. Participants who have undergone ocular surgery of clinical relevance (per Investigator opinion) within 90 days preceding the Screening Visit (Visit 1).
• •18. Female participants who are or who intend to breast feed during the trial period.
• •Participants who meet at least one of the following criteria at the Inclusion Visit (Visit 2) will not be included in the study.
• •1. Any non-selection criteria which may have appeared after the screening visit.
• •2. Participants taking idebenone who have not completely discontinued the idebenone at least 7 days prior to Visit 2. If the participant has not discontinued idebenone at least 7 days prior to Visit 2, the visit may be delayed until the 7-day period is complete.
• •3. Presence, at the time of study inclusion, of infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye.
• •4. Presence of systemic illness, including alcohol and drug abuse (except nicotine), or medically significant abnormal laboratory values that are deemed by the Investigator to preclude the participant's safe participation in the study.
• •5. Presence of illness or disease that, in the opinion of the Investigator, include symptoms and/or the associated treatments that can alter visual function, for instance cancers or pathology of the central nervous system.
• •6. Any medical or psychological condition that, in the opinion of the Investigator, may compromise the safe participation of the participant in the study or would preclude compliance with the study protocol or ability of the participant to successfully complete the study.
• •7. Participants unable or unwilling to comply with the protocol requirements.